Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Lymphoid Leukemias, ALL, Adult, Autoimmune hemolytic anemia, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Infusion, Young adult , Human, Study Population, Transplantation (Allogeneic and Autologous)
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Lymphoid Leukemias, ALL, Adult, Autoimmune hemolytic anemia, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Infusion, Young adult , Human, Study Population, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024: 4:30 PM-6:00 PM
Marriott Grand Ballroom 2-4
(Marriott Marquis San Diego Marina)
Moderators:
Jennifer N Brudno, MD, National Cancer Institute, National Institutes of Health
and
Alexandre V. Hirayama, MD, ARRAY(0xea61c44)
Disclosures:
Hirayama: Juno Therapeutics, a Bristol Myers Squibb Company: Honoraria, Research Funding; Nektar Therapeutics: Research Funding.
4:30 PM
4:45 PM
5:00 PM
5:30 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH